Ohtani Hayato

Lidre Inc. is a Tokyo-based biotechnology company specializing in the discovery and development of next-generation macrocyclic peptide therapeutics. Founded in 2023 by CEO Hayato Ohtani and Professor Hiroaki Suga of the University of Tokyo, the company utilizes the advanced RaPID (Random non-standard Peptides Integrated Discovery) system. This platform enables the rapid identification of highly potent and selective non-standard peptides that can modulate challenging targets, such as protein-protein interactions, which are often inaccessible to small molecules. Lidre aims to leverage its technology to create a robust pipeline of innovative drugs for various diseases with high unmet medical needs. The company represents a significant spin-off from the University of Tokyo's research into genetic code expansion and mRNA display.